In the beginning there was a small group of dedicated scientists who were wondering if it was possible to change the way people monitor their health.
They created a Highly Specialized Molecular Testing Company based on Co-operation
Since Genomic testing is expensive and risky for smaller labs they established GTC, a genomic testing lab combining next-gen sequencing (NGS) with AI that will disrupt the current model.
GTC WAS FOUNDED IN 2018.
We strive to offer advanced genomic testing to communities everywhere at an affordable price.
We utilize a cooperative business model that enables academic and commercial laboratories to help physicians treat patients locally with the most advanced precision medicine.
We embrace disruptive deep learning and advanced technology to create scalable efficiencies, incomparable precision, and a more personalized approach to patient care.
We are committed to driving the field of oncology forward by enabling more patients to contribute their unique cancer experience to the growing body of cancer genomics data.
We are committed to fulfilling precision medicine’s promise of individualized care for everyone by empowering physicians to formulate treatments that best suit each patient’s unique genetic profile.
Because cancer is an expensive disease to fight we put patients before profits and charge fair prices. Everyone should have the opportunity to contribute their unique cancer fingerprint to the knowledge base and so we all get closer to breakthroughs.
Our goal is to take genomic testing to the level that precision medicine fulfills its promise in oncology of treating every patients’ cancer.
THEY HAVE WORKED FOR SCIENCE, FOR RESEARCH AND DEVELOPMENT AND FOR GTC PROJECT FOR MORE THAN THOUSANDS OF HOURS.
Dr. Maher Albitar is the founder and CEO of Genomic Testing Cooperative, LCA. Dr. Albitar has extensive experience in anatomic/clinical pathology, hematopathology, and molecular pathology. He also has extensive business and administrative experience as an executive leader of large laboratories, Board member, and director of large scientific and genomic diagnostic studies. Until recently, Dr. Albitar was the Senior Vice President, Chief Medical Officer and Director of Research and Development at NeoGenomics. He is credit of transforming the NeoGenomics Laboratories from FISH testing company to a company offering the most sophisticated molecular testing. Prior to NeoGenomics, Dr. Albitar served as the…
Lawrence has extensive ( 39 years) experience in clinical laboratory testing, accreditation, automation, and management. From 2012 until 2018, Lawrence was Director of the molecular laboratory at NeoGemoics. From 2003 to 2012 he was at Nichols Institute, Quest Diagnostic as a manager of Biochemical Genetics, first, then Hematology/Oncology. Prior to that, he worked in leadership positions at multiple clinical laboratories including Prometheus, Group Health Cooperative, US Laboratories, OncoTech, and SmithKline Beecham. Lawrence has a bachelor of science degree in biology from California State University. He is licensed as a Clinical Laboratory Scientist by the State of California and ASCP certified.
Personalized medicine aided by AI
Transforming diagnostic testing by adapting AI
Interpreting NGS data using machine learning
Transforming diagnostic testing by adapting AI
Interpreting NGS data using deep learning
Order Solid Tumor Fusion/Expression. It can detect all fusions described in sarcoma, in addition it also detects mutations in most relevant genes. This helps in diagnosis, classification and determining therapy of sarcoma.
Order Hematology Fusion/Expression test. This test will classify the DLBCL into ABC vs GCB and gives you all mutations and help in selecting therapy and predicting outcome. Our test is the only test on the market that give you GCB vs ABC classification by expression profiling, which is significantly more accurate than IHC, and at the same time gives you mutation profile.
Order Hematology Fusion/Expression test
Order the GTC Solid tumor profile. This test will give results of mutations amplification of 434 genes (including EGFR, RAS, BRAF…), but in addition, it will give results on microsatellite instability (MSI) testing and Tumor Mutation Burdon (TMB). However, if you wants information on translocation of ALK, ROS1, and RET, you need to order the GTC Solid Tumor PLUS.